Inflammatory bowel disease: new insights into pathogenesis and treatment

被引:123
作者
Ardizzone, S [1 ]
Porro, GB [1 ]
机构
[1] L Sacco Univ Hosp, Chair Gastroenterol, Milan, Italy
关键词
Crohn's disease; pathogenesis; therapy; ulcerative colitis;
D O I
10.1046/j.1365-2796.2002.01067.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite all the advances in our understanding of the pathophysiology of inflammatory bowel disease (IBD), we do not know the cause. Some of the most recently available data have been discussed here and yet it is now becoming increasingly accepted that immunogenetics play an important role in the predisposition, modulation, and perpetuation of IBD. The mucosal immune system is the central effector of intestinal inflammation and injury, with cytokines playing a central role in modulating inflammation. The role of intestinal milium, and enteric flora in particular, appears to be of greater significance than previously held. A review is made of the main areas of research exploring the mechanisms more intimately associated with the development of IBD, providing advances in the agents currently used, and identifying a host of new therapeutic agents potentially interacting with or interrupting specific targets in the genesis of IBD.
引用
收藏
页码:475 / 496
页数:22
相关论文
共 182 条
  • [41] Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease
    Darfeuille-Michaud, A
    Neut, C
    Barnich, N
    Lederman, E
    Di Martino, P
    Desreumaux, P
    Gambiez, L
    Joly, B
    Cortot, A
    Colombel, JF
    [J]. GASTROENTEROLOGY, 1998, 115 (06) : 1405 - 1413
  • [42] DEUSCH K, 1993, GASTROENTEROLOGY, V104, pA691
  • [43] Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
    Dubinsky, MC
    Lamothe, S
    Yang, HY
    Targan, SR
    Sinnett, D
    Théorêt, Y
    Seidman, EG
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : 705 - 713
  • [44] Dubuquoy L, 2000, GASTROEN CLIN BIOL, V24, P719
  • [45] T cell specificity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans
    Duchmann, R
    May, E
    Heike, M
    Knolle, P
    Neurath, M
    zum Büschenfelde, KHM
    [J]. GUT, 1999, 44 (06) : 812 - 818
  • [46] Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448
  • [47] Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
    Ehrenpreis, ED
    Kane, SV
    Cohen, LB
    Cohen, RD
    Hanauer, SB
    [J]. GASTROENTEROLOGY, 1999, 117 (06) : 1271 - 1277
  • [48] ELLIOTT DE, 2000, FASEB J, V4, P430
  • [49] Commensal bacteria as targets in Crohn's disease
    Elson, CO
    [J]. GASTROENTEROLOGY, 2000, 119 (01) : 254 - 257
  • [50] TREATMENT OF INFLAMMATORY BOWEL-DISEASE WITH ANTI-CD4 MONOCLONAL-ANTIBODY
    EMMRICH, J
    SEYFARTH, M
    FLEIG, WE
    EMMRICH, F
    [J]. LANCET, 1991, 338 (8766) : 570 - 571